These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8480686)

  • 1. Effect of chemotherapy on the energy and protein metabolism of children near the end of treatment for acute lymphoblastic leukemia.
    Vaisman N; Stallings VA; Chan H; Weitzman SS; Clarke R; Pencharz PB
    Am J Clin Nutr; 1993 May; 57(5):679-84. PubMed ID: 8480686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
    Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
    J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
    Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukemia: urinary assays as a measure of drug compliance.
    Macdougall LG; McElligott SE; Ross E; Greeff MC; Poole JE
    Ther Drug Monit; 1992 Oct; 14(5):371-5. PubMed ID: 1448843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
    Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
    Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
    Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance Treatment in Acute Lymphoblastic Leukemia: A Clinical Primer.
    Krishnan S; Mahadevan A; Mungle T; Gogoi MP; Saha V
    Indian J Pediatr; 2024 Jan; 91(1):47-58. PubMed ID: 37493925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
    J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
    Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
    Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploration of mercaptopurine/methotrexate tolerance during maintenance therapy in children with acute lymphoblastic leukemia.
    Whiley AC; Price V; MacDonald T
    J Oncol Pharm Pract; 2021 Oct; 27(7):1631-1636. PubMed ID: 33040672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.
    Halonen P; Mattila J; Mäkipernaa A; Ruuska T; Schmiegelow K
    Pediatr Blood Cancer; 2006 Jun; 46(7):762-6. PubMed ID: 16395677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
    Giverhaug T; Loennechen T; Aarbakke J
    Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
    Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
    J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Zuccaro P; Guandalini S; Pacifici R; Pichini S; Di Martino L; Guiducci M; Giuliano M; Di Tullio MT; Pettoello Mantovani M
    Ther Drug Monit; 1991 Jan; 13(1):37-41. PubMed ID: 2057989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.